NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.

  title={NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.},
  author={M. Daly and R. Pilarski and Michael P Berry and S. Buys and M. Farmer and S. Friedman and J. Garber and N. Kauff and Seema A. Khan and C. Klein and W. Kohlmann and A. Kurian and J. Litton and L. Madlensky and S. Merajver and K. Offit and T. Pal and Gwen Reiser and K. Shannon and E. Swisher and S. Vinayak and Nicoleta C. Voian and J. Weitzel and M. Wick and G. Wiesner and M. Dwyer and S. Darlow},
  journal={Journal of the National Comprehensive Cancer Network : JNCCN},
  volume={15 1},
The NCCN Clinical Practice Guidelines in Oncology for Genetic/Familial High-Risk Assessment: Breast and Ovarian provide recommendations for genetic testing and counseling for hereditary cancer syndromes and risk management recommendations for patients who are diagnosed with a syndrome. Guidelines focus on syndromes associated with an increased risk of breast and/or ovarian cancer. The NCCN Genetic/Familial High-Risk Assessment: Breast and Ovarian panel meets at least annually to review comments… Expand
The Changing Landscape of Genetic Testing for Inherited Breast Cancer Predisposition
Events leading to the wider availability of commercialized multiple-gene germline panel testing, the recent data that support using this powerful tool to improve cancer risk assessment and reduction strategies, and remaining challenges to clinical optimization of this new genetic technology are discussed. Expand
Selecting Patients with Ovarian Cancer for Germline BRCA Mutation Testing: Findings from Guidelines and a Systematic Literature Review
IntroductionOne of the most significant risk factors for the development of ovarian cancer (OC) is a genetic mutation in BRCA1 (breast cancer gene 1) or BRCA2. Here we describe the impact of previousExpand
Genetic Testing to Guide Risk-Stratified Screens for Breast Cancer
Genetic testing of high-penetrance hereditary breast and ovarian cancer genes, including BRCA1 and BRCa2, is reviewed for the purpose of identifying high-risk individuals who would benefit from earlier screening and more sensitive methods such as magnetic resonance imaging. Expand
Management of the Patient with a Genetic Predisposition for Breast Cancer
Current methods for risk assessment, genetic counseling and testing, and management of individuals at hereditary risk for breast cancer will be covered, as well as resources for including these activities into clinical practice. Expand
Barriers to the utilization of genetic testing and genetic counseling in patients with suspected hereditary breast and ovarian cancers
The largest obstacle to receiving genetic testing and/or counseling was lack of referral from the treating oncologist, and the initial referral to genetic counseling is the most significant barrier for at-risk patients at this institution and likely in this population at large. Expand
When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges
The challenges for health professionals and patients in understanding and balancing the risks and benefits of major prophylactic surgery in the context of a potentially life-limiting cancer diagnosis are focused on. Expand
A new paradigm of genetic testing for hereditary breast/ovarian cancers.
Multi-gene testing, if used appropriately, is generally a more cost- and time-effective method than single-gree testing, and may increase the number of patients who can be offered personal surveillance, risk-reduction options, and testing of high-risk family members. Expand
Risk of Prostate Cancer Associated With Familial and Hereditary Cancer Syndromes.
In this large, population-based, family database, the risk of PC varied by cancer FH and was most strongly associated with EO disease. Expand
Current and future role of genetic screening in gynecologic malignancies
The objective of this review is to present the current literature regarding genetic mutations associated with gynecologic malignancies as well to propose screening and risk‐reduction options for these high‐risk patients. Expand
Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.
All patients with invasive epithelial OC (excluding borderline or mucinous), including those with fallopian tube and peritoneal cancers, should be considered as candidates for referral for BRCA genetic testing, irrespective of age. Expand